The reduction in price target could have a mixed impact on Rallybio's stock. On one hand, the lowered price target might suggest a tempered outlook, potentially leading to short-term negative sentiment among investors. On the other hand, maintaining a Buy rating indicates a positive view on the company's fundamentals and potential for growth, which could mitigate negative reactions. The net impact is considered neutral due to these counterbalancing factors.